Schedule 13G

-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, RoxRIB/SIQbvJBYE8CWjIgzrnIN+CEes7sTqkwahNJoFAcSYb0UlzIzEcdUBdmxn v8KcNJSey+LUT3+3QrjCSA== 0001193125-05-114882.txt : 20050611 0001193125-05-114882.hdr.sgml : 20050611 20050525172618 ACCESSION NUMBER: 0001193125-05-114882 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050525 DATE AS OF CHANGE: 20050525 GROUP MEMBERS: COSTA BRAVA PARTNERSHIP III L.P. GROUP MEMBERS: ROARK, REARDEN & HAMOT LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: BRADLEY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000864268 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222581418 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-43138 FILM NUMBER: 05857656 BUSINESS ADDRESS: STREET 1: 383 RTE 46 WEST CITY: FAIRFIELD STATE: NJ ZIP: 08816 BUSINESS PHONE: 9738821505 MAIL ADDRESS: STREET 1: 383 ROUTE 46 WEST CITY: FAIRFIELD STATE: NJ ZIP: 08816 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HAMOT SETH W CENTRAL INDEX KEY: 0001071036 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 35 HANCVOCK STREET CITY: BOSTON STATE: MA ZIP: 02108 BUSINESS PHONE: 6172278156 MAIL ADDRESS: STREET 1: 35 HANCOCK STREET CITY: BOSTON STATE: MA ZIP: 02108 SC 13G 1 dsc13g.htm SCHEDULE 13G Schedule 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )

Bradley Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.01 Par Value

(Title of Class of Securities)

104576 10 3

(CUSIP Number)

May 17, 2005

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)


CUSIP No.: 104576 10 3		13G		Page 2 of 8 Pages


1.		Names of Reporting Persons: I.R.S. Identification Nos. of above persons (entities only): Seth W. Hamot
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Citizenship or Place of Organization: United States

Number of

Beneficially

Owned by

Each Reporting

Person With

5. Sole Voting Power:

898,200¹

6. Shared Voting Power:

-0-

7. Sole Dispositive Power:

898,200¹

8. Shared Dispositive Power:

-0-


9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 898,200¹
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):	¨
11.	Percent of Class Represented by Amount in Row (9): 5.8%
12.	Type of Reporting Person (See Instructions): IN, HC

¹	The reporting person beneficially owned 898,200 shares of common stock of Bradley Pharmaceuticals, Inc. as of May 25, 2005.


CUSIP No.: 104576 10 3		13G		Page 3 of 8 Pages


1.		Names of Reporting Persons: I.R.S. Identification Nos. of above persons (entities only): Costa Brava Partnership III L.P. 04-3387028
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Citizenship or Place of Organization: Delaware

Number of

Beneficially

Owned by

Each Reporting

Person With

5. Sole Voting Power:

898,200²

6. Shared Voting Power:

-0-

7. Sole Dispositive Power:

898,200²

8. Shared Dispositive Power:

-0-


9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 898,200²
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):	¨
11.	Percent of Class Represented by Amount in Row (9): 5.8%
12.	Type of Reporting Person (See Instructions): PN

²	The reporting person beneficially owned 898,200 shares of common stock of Bradley Pharmaceuticals, Inc. as of May 25, 2005.


CUSIP No.: 104576 10 3		13G		Page 4 of 8 Pages


1.		Names of Reporting Persons: I.R.S. Identification Nos. of above persons (entities only): Roark, Rearden & Hamot LLC 10-0000708
2.		Check the Appropriate Box if a Member of a Group (See Instructions) (a) ¨ (b) ¨
3.		SEC Use Only
4.		Citizenship or Place of Organization: Delaware

Number of

Beneficially

Owned by

Each Reporting

Person With

5. Sole Voting Power:

898,200³

6. Shared Voting Power:

-0-

7. Sole Dispositive Power:

898,200³

8. Shared Dispositive Power:

-0-


9.	Aggregate Amount Beneficially Owned by Each Reporting Person: 898,200³
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions):	¨
11.	Percent of Class Represented by Amount in Row (9): 5.8%
12.	Type of Reporting Person (See Instructions): OO - Other

³	The reporting person beneficially owned 898,200 shares of common stock of Bradley Pharmaceuticals, Inc. as of May 25, 2005.


				Page 5 of 8 Pages

Item 1.

(a)

Name of Issuer:

Bradley Pharmaceuticals, Inc.

(b)

Address of Issuer’s Principal Executive Offices:

383 Route 46 West

Fairfield, NJ 07004

Item 2.

(a)

Name of Person Filing:

Seth W. Hamot is the president of Roark, Reardon & Hamot LLC, which is the general partner of Costa Brava Partnership III L.P. All of the shares of common stock that were beneficially owned by the reporting persons were held by Costa Brava Partnership III L.P.

(b)

Address of Principal Business Office or, if None, Residence:

The principal business address of each of Seth Hamot, Roark, Rearden & Hamot LLC and Costa Brava Partnership III L.P. is 68 Harvard Street, 3rd Floor, Brookline, MA 02445.

(c)

Citizenship:

Seth W. Hamot is a United States citizen. Costa Brava Partnership III L.P. is a Delaware limited partnership. Roark, Rearden & Hamot LLC is a Delaware limited liability company.

(d)

Title of Class of Securities:

Common Stock, $0.01 Par Value

(e)

CUSIP Number:

104576 10 3

Item 3.

If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

(e)

An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

Group, in accordance with §240.13d-1(b)(1)(ii)(J).


				Page 6 of 8 Pages



Item 4.		Ownership.

		With respect to the beneficial ownership of shares of common stock of Bradley Pharmaceuticals, Inc. by the reporting persons, see Items 5 through 11 of the cover pages of this Schedule 13G, which are incorporated herein by reference.

Item 5.		Ownership of Five Percent or Less of a Class

		If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨.

Item 6.		Ownership of More than Five Percent on Behalf of Another Person.

		Not applicable.

Item 7.		Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

		Not applicable.

Item 8.		Identification and Classification of Members of the Group

		Not applicable.

Item 9.		Notice of Dissolution of Group

		Not applicable.

Item 10.		Certification

		By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

		The reporting persons have agreed that this Schedule may be filed by Seth W. Hamot on behalf of all of them jointly pursuant to Rule 13d-1(k)(1). A copy of such agreement is attached as an Exhibit to this Schedule.


				Page 7 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

May 25, 2005

Date

/s/ Seth W. Hamot

Seth W. Hamot


				Page 8 of 8 Pages

EXHIBIT INDEX


Exhibit 1		Agreement Regarding the Joint Filing of Schedule 13G

EX-1 2 dex1.htm AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13G Agreement Regarding the Joint Filing of Schedule 13G

Exhibit 1

AGREEMENT REGARDING

THE JOINT FILING OF SCHEDULE 13G

The undersigned hereby agree as follows:

(i) Each of them is individually eligible to use the Schedule 13G to which this Exhibit is attached, and such Schedule 13G is filed on behalf of each of them; and

(ii) Each of them is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

Dated: May 25, 2005


COSTA BRAVA PARTNERSHIP III L.P.

By:		/s/ Seth W. Hamot
		Roark, Rearden & Hamot LLC,
		General Partner
by:		Seth W. Hamot
		President

SETH W. HAMOT

By:		/s/ Seth W. Hamot
		Seth W. Hamot

ROARK, REARDEN & HAMOT LLC

By:		/s/ Seth W. Hamot
		Seth W. Hamot
		President

-----END PRIVACY-ENHANCED MESSAGE-----